Sugi Predict

Sugi Predict / Compounds / SCHEMBL4760474

SCHEMBL4760474

SCHEMBL4760474

CN(C)C(=O)[C@H]1CC[C@@H](N)CC1

nearest known ligand 0.37

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ GLI1 P08151 1/20 0.35
▸ SMYD3 Q9H7B4 2/20 0.33
▸ BCHE P06276 1/20 0.33
▸ DPP4 P27487 1/20 0.33
▸ MME P08473 1/20 0.32
▸ CYP2D6 P10635 1/20 0.31
▸ HSD11B1 P28845 1/20 0.31
▸ CYP46A1 Q9Y6A2 3/20 0.31
▸ HTT P42858 1/20 0.31
▸ BTK Q06187 1/20 0.30
▸ CTSB P07858 1/20 0.30
▸ CTSS P25774 1/20 0.30
▸ CTSK P43235 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4103676 1.00 GLI1 (0.35) GLI1SMYD3BCHEDPP4MME
SCHEMBL1543311 1.00 GLI1 (0.35) GLI1SMYD3BCHEDPP4MME
Hydrochloric Acid SCHEMBL2804477 0.98 GLI1 (0.34) GLI1SMYD3BCHEDPP4MME
Hydrochloric Acid SCHEMBL13275366 0.98 GLI1 (0.34) GLI1SMYD3BCHEDPP4MME
Hydrochloric Acid SCHEMBL17889948 0.98 GLI1 (0.34) GLI1SMYD3BCHEDPP4MME
SCHEMBL197080 0.87 — —
SCHEMBL21545609 0.87 GLI1 (0.41) GLI1BCHEDPP4MMECYP2D6
SCHEMBL4760467 0.86 DPP4 (0.34) GLI1BCHEDPP4
SCHEMBL3346344 0.81 SMN1; SMN2 (0.42) GLI1BCHEDPP4MMECYP2D6
Carbamic Acid SCHEMBL11685067 0.81 GLI1 (0.35) GLI1BCHEDPP4MMECYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12454547-B2 Steroidal compositions and methods of treating lipogenic cancers Asteroid Therapeutics (US) 2025-10-28 — — US disclosed
US-12258328-B2 6-membered heteroaryl-containing aminopyridine compounds as EGFR inhibitors YUHAN CORPORATION (KR) 2025-03-25 — — US disclosed
US-12258327-B2 5-membered heteroaryl-containing aminopyridine compounds as EGFR inhibitors YUHAN CORPORATION (KR) 2025-03-25 — — US disclosed
CN-119604506-A 4-Alkoxypyrrolo [2,1-f ] [1,2,4] triazines, preparation and use thereof 拜斯丽治疗有限公司 2025-03-11 — — CN disclosed
EP-4415816-A1 PYRROLO[2,1-F][1,2,4]TRIAZINES DERIVATIVES AS INHIBITORS OF DYRK1A BioSplice Therapeutics, Inc. (US) 2024-08-21 — — EP disclosed
CN-118488954-A Pyrrolo [2,1-F ] [1,2,4] triazine derivatives as DYRK1A inhibitors 拜斯丽治疗有限公司 2024-08-13 — — CN disclosed
WO-2023250156-A1 4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF BIOSPLICE THERAPEUTICS, INC. (US) 2023-12-28 — — WO disclosed
WO-2023205801-A2 STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS Asteroid Therapeutics (US) 2023-10-26 — — WO disclosed
WO-2023205801-A2 STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS Asteroid Therapeutics (US) 2023-10-26 — — WO disclosed
US-20230340011-A1 STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS Asteroid Therapeutics 2023-10-26 — — US disclosed
US-8039470-B2 Kinase inhibitor compounds TYROGENEX, INC. (US) 2011-10-18 — — US disclosed
US-8039470-B2 Kinase inhibitor compounds TYROGENEX, INC. (US) 2011-10-18 — — US disclosed
US-20110224212-A1 KINASE INHIBITOR COMPOUNDS TYROGENEX, INC. (US) 2011-09-15 — — US disclosed
US-20110224212-A1 KINASE INHIBITOR COMPOUNDS TYROGENEX, INC. (US) 2011-09-15 — — US disclosed
US-20100261665-A1 Kinase inhibitor compounds XCOVERY, INC. (US) 2010-10-14 — — US disclosed
US-20100261665-A1 Kinase inhibitor compounds XCOVERY, INC. (US) 2010-10-14 — — US disclosed
US-7683057-B2 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (1-acetyl-piperidin-4-yl)-amide; inhibition of 5' AMP-activated protein kinase (AMPK) TYROGENEX, INC. (US) 2010-03-23 — — US disclosed
US-7683057-B2 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (1-acetyl-piperidin-4-yl)-amide; inhibition of 5' AMP-activated protein kinase (AMPK) TYROGENEX, INC. (US) 2010-03-23 — — US disclosed
US-20090076005-A1 Kinase inhibitor compounds XCOVERY, INC. (US) 2009-03-19 — — US disclosed
US-20090076005-A1 Kinase inhibitor compounds XCOVERY, INC. (US) 2009-03-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12454547-B2 Steroidal compositions and methods of treating lipogenic cancers SREBF1, SREBF2, NR1H3 GLI1 451/4885SMYD3 1502/4885BCHE 3797/4885
US-20090076005-A1 Kinase inhibitor compounds MAP3K1, MAP3K20, MAP3K2 GLI1 1996/4885SMYD3 2070/4885BCHE 2056/4885
US-20100261665-A1 Kinase inhibitor compounds MAP3K1, MAP3K20, MAP3K2 GLI1 1996/4885SMYD3 2070/4885BCHE 2056/4885
US-20230340011-A1 STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS SREBF1, SREBF2, NR1H3 GLI1 451/4885SMYD3 1502/4885BCHE 3797/4885
US-20110224212-A1 KINASE INHIBITOR COMPOUNDS MAP3K1, MAP3K20, MAP3K2 GLI1 1996/4885SMYD3 2070/4885BCHE 2056/4885
US-12258327-B2 5-membered heteroaryl-containing aminopyridine compounds as EGFR inhibitors EGFR, ERBB2, ERBB4 GLI1 355/4885SMYD3 3698/4885BCHE 4078/4885
US-12258328-B2 6-membered heteroaryl-containing aminopyridine compounds as EGFR inhibitors EGFR, ERBB2, ERBB4 GLI1 316/4885SMYD3 3674/4885BCHE 3854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.